Tremeau and FDA Agree on Phase 3 Plan to Test Rofecoxib in Hemophilia Joint Pain
News
Tremeau Pharmaceuticals has received guidance from the U.S. Food and Drug Administration (FDA) on how to conduct a pivotal Phase 3 trial exploring rofecoxib (TRM-201) in patients with hemophilia-associated joint ... Read more